[Spin on]
[Spin off]
[Reset]
[High quality]
[Low quality]
[White background]
[Black background]
|
[Spin on]
[Spin off]
[Reset]
[High quality]
[Low quality]
[White background]
[Black background]
|
PDB | 8coh Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. |
Resolution | 1.3 Å |
Binding residue (original residue number in PDB) | H127 H129 |
Binding residue (residue number reindexed from 1) | H127 H129 |
Annotation score | 4 |
|